Long-term survival and relapse patterns in FLT3-mutated AML treated with frontline triplet therapy
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-12-13
Просмотров: 624
Описание:
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a retrospective analysis exploring the value of a triplet regimen of a hypomethylating agent (HMA), venetoclax, and a FLT3 inhibitor in treating adults with FLT3-mutated acute myeloid leukemia (AML). The analysis demonstrated that this regimen has shown excellent long-term survival outcomes, with higher overall survival (OS) rates than have historically been observed with a doublet of HMA and venetoclax. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
